Patients with lower expression of ROCK1 in the central tumour and invasive front had lower recurrence-free survival rates (p = 0.004 and p = 0.001, respectively; Figure 4A and B), and those with weak ROCK1 expression in the invasive front experienced lower cancer-specific survival (p <0.001; Figure 4C and D). Here, ROCK1 is linked to cancer.